No Data
Novo Nordisk Q3 Wegovy revenue surged by 79%, narrowing the full-year sales guidance range.
Novo Nordisk's net income in the third quarter was 27.301 billion Danish krone, a 21% year-on-year increase, exceeding the market's expected 26.7 billion Danish krone. Wegovy's revenue increased by 79% to 17.3 billion Danish krone, surpassing the expected 15.6 billion Danish krone, with sales in the USA increasing by about 50%.
SA Asks: How Will the U.S. Election Results Impact Healthcare Stocks?
Trending: Novo Nordisk Posts Higher 3Q Profit
Forecasting The Future: 7 Analyst Projections For Novo Nordisk
Novo Nordisk warns of the risks of compound generic drugs, stating that 10 people have died and more than 100 people have been hospitalized.
①The chief financial officer of novo-nordisk a/s stated that 10 people have died after taking complex generic weight loss pharmaceuticals, with another 100 hospitalized. ②novo-nordisk a/s has requested the FDA to include semaglutide in the 'Provable Synthetic Difficulty List' to restrict generic production. The company will continue to engage in dialogue with the FDA to address pharmaceutical access issues.
Sector Update: Health Care Stocks Mixed Wednesday Afternoon
No Data
No Data
